Literature DB >> 1423299

Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers.

Y Huang1, R F Boynton, P L Blount, R J Silverstein, J Yin, Y Tong, T K McDaniel, C Newkirk, J H Resau, R Sridhara, B J Reid, S J Meltzer.   

Abstract

Loss of heterozygosity occurring on various chromosomes has been described in the majority of human tumors. The targets of frequent or consistent subchromosomal deletions are believed to be tumor suppressor genes. We examined 72 esophageal tumors (46 squamous cell carcinomas and 26 adenocarcinomas) for loss of heterozygosity at the p53, Rb, APC, MCC, and DCC loci. Inclusion of these tumor suppressor genes in the allelic deletions was directly ascertained by performing polymerase chain reaction at polymorphic sites within the genes. Loss of heterozygosity occurred in 55% of informative cases at p53, in 48% of informative cases at Rb, in 66% at APC, in 63% at MCC, and in 24% at DCC. Ninety-three % of tumors informative at all loci (fully informative) lost heterozygosity of at least one locus. A high percentage of fully informative tumors (71%) also lost heterozygosity at more than one locus. There were no significant differences among histological types in the prevalence of loss of heterozygosity at any locus. There were correlations of losses involving MCC versus DCC, Rb, and p53. These data suggest that (a) allelic deletions including these tumor suppressor genes are important in the formation and/or progression of most esophageal cancers; (b) allelic deletions involving MCC may not occur independently of deletions involving other tumor suppressor genes; and (c) the accumulation of multiple allelic deletions involving specific tumor suppressor genes may be important in most esophageal tumorigenesis or tumor evolution.

Entities:  

Mesh:

Year:  1992        PMID: 1423299

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

Authors:  J A Jankowski; N A Wright; S J Meltzer; G Triadafilopoulos; K Geboes; A G Casson; D Kerr; L S Young
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.

Authors:  P C Galipeau; D S Cowan; C A Sanchez; M T Barrett; M J Emond; D S Levine; P S Rabinovitch; B J Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas.

Authors:  M Saegusa; Y Takano; Y Kamata; J Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival.

Authors:  A Hara; M Saegusa; T Mikami; I Okayasu
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

6.  Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer.

Authors:  D C Fang; J R Jass; D X Wang
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

7.  Decreased expression of the DCC gene in human breast carcinoma.

Authors:  K Wakita; N Kohno; Y Sakoda; Y Ishikawa; M Sakaue
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

8.  Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus.

Authors:  Kun Jiang; Kevin Neill; Daniel Cowden; Jason Klapman; Steven Eschrich; José Pimiento; Mokenge P Malafa; Domenico Coppola
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

9.  Isolation of differentially expressed genes in carcinoma of the esophagus.

Authors:  M W Graber; C W Schweinfest; C E Reed; T S Papas; P L Baron
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

10.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Authors:  R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.